These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
456 related articles for article (PubMed ID: 27543806)
1. A common reference-based indirect comparison meta-analysis of eslicarbazepine versus lacosamide as add on treatments for focal epilepsy. Brigo F; Trinka E; Bragazzi NL; Nardone R; Milan A; Grillo E Epilepsy Res; 2016 Nov; 127():12-18. PubMed ID: 27543806 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: Results of an indirect comparison meta-analysis of RCTs. Brigo F; Bragazzi NL; Nardone R; Trinka E Seizure; 2016 Nov; 42():29-37. PubMed ID: 27710868 [TBL] [Abstract][Full Text] [Related]
3. Neurological adverse events of new generation sodium blocker antiepileptic drugs. Meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine. Zaccara G; Giovannelli F; Maratea D; Fadda V; Verrotti A Seizure; 2013 Sep; 22(7):528-36. PubMed ID: 23623245 [TBL] [Abstract][Full Text] [Related]
4. Third-Generation Antiseizure Medications for Adjunctive Treatment of Focal-Onset Seizures in Adults: A Systematic Review and Network Meta-analysis. Lattanzi S; Trinka E; Zaccara G; Striano P; Russo E; Del Giovane C; Silvestrini M; Brigo F Drugs; 2022 Feb; 82(2):199-218. PubMed ID: 35061214 [TBL] [Abstract][Full Text] [Related]
5. Eslicarbazepine acetate add-on therapy for drug-resistant focal epilepsy. Chang XC; Yuan H; Wang Y; Xu HQ; Hong WK; Zheng RY Cochrane Database Syst Rev; 2021 Jun; 6(6):CD008907. PubMed ID: 34155624 [TBL] [Abstract][Full Text] [Related]
7. Eslicarbazepine acetate add-on for drug-resistant partial epilepsy. Chang XC; Yuan H; Wang Y; Xu HQ; Hong WK; Zheng RY Cochrane Database Syst Rev; 2017 Oct; 10(10):CD008907. PubMed ID: 29067682 [TBL] [Abstract][Full Text] [Related]
8. Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis. Lattanzi S; Zaccara G; Giovannelli F; Grillo E; Nardone R; Silvestrini M; Trinka E; Brigo F Acta Neurol Scand; 2019 Jan; 139(1):33-41. PubMed ID: 30194755 [TBL] [Abstract][Full Text] [Related]
9. Indirect comparison of third-generation antiepileptic drugs as adjunctive treatment for uncontrolled focal epilepsy. Li-Na Z; Deng C; Hai-Jiao W; Da X; Ge T; Ling L Epilepsy Res; 2018 Jan; 139():60-72. PubMed ID: 29197667 [TBL] [Abstract][Full Text] [Related]
10. Adjunctive lacosamide in clinical practice: sodium blockade with a difference? Stephen LJ; Kelly K; Parker P; Brodie MJ Epilepsy Behav; 2011 Nov; 22(3):499-504. PubMed ID: 21890421 [TBL] [Abstract][Full Text] [Related]
11. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group. Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754 [TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study. Trinka E; Rocamora R; Chaves J; Moreira J; Ikedo F; Soares-da-Silva P; Epilepsia; 2020 Oct; 61(10):2129-2141. PubMed ID: 32944934 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of adjuvant lacosamide: The role of clinical characteristics and mechanisms of action of concomitant AEDs. Neal A; D'Souza W; Hepworth G; Lawn N; Cook M; Nikpour A Epilepsy Behav; 2018 Mar; 80():25-32. PubMed ID: 29396359 [TBL] [Abstract][Full Text] [Related]
14. Newer antiepileptic drugs compared to levetiracetam as adjunctive treatments for uncontrolled focal epilepsy: An indirect comparison. Zhu LN; Chen D; Xu D; Tan G; Wang HJ; Liu L Seizure; 2017 Oct; 51():121-132. PubMed ID: 28854405 [TBL] [Abstract][Full Text] [Related]
15. Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies. Shorvon SD; Trinka E; Steinhoff BJ; Holtkamp M; Villanueva V; Peltola J; Ben-Menachem E J Neurol; 2017 Mar; 264(3):421-431. PubMed ID: 28101651 [TBL] [Abstract][Full Text] [Related]
17. Real-world data on eslicarbazepine acetate as add-on to antiepileptic monotherapy. Holtkamp M; McMurray R; Bagul M; Sousa R; Kockelmann E Acta Neurol Scand; 2016 Jul; 134(1):76-82. PubMed ID: 26915469 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: integrated analysis of pooled data from double-blind phase III clinical studies. Gil-Nagel A; Elger C; Ben-Menachem E; Halász P; Lopes-Lima J; Gabbai AA; Nunes T; Falcão A; Almeida L; da-Silva PS Epilepsia; 2013 Jan; 54(1):98-107. PubMed ID: 22882018 [TBL] [Abstract][Full Text] [Related]
19. Real life pharmaceutical treatment patterns for adult patients with focal epilepsy in Germany: a longitudinal and cross-sectional analysis of recently approved anti-epileptic drugs. Groth A; Wilke T; Borghs S; Gille P; Joeres L Ger Med Sci; 2017; 15():Doc09. PubMed ID: 28638313 [No Abstract] [Full Text] [Related]
20. Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies. Elger C; Koepp M; Trinka E; Villanueva V; Chaves J; Ben-Menachen E; Kowacs PA; Gil-Nagel A; Moreira J; Gama H; Rocha JF; Soares-da-Silva P CNS Neurosci Ther; 2017 Dec; 23(12):961-972. PubMed ID: 29030894 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]